Renalytix AI PLC US CPT® reimbursement code effective (2455O)

TIDMRENX

RNS Number : 2455O

Renalytix AI PLC

01 October 2019

Renalytix AI plc

("RenalytixAI", the "Company" or the "Group")

US CPT(R) reimbursement code effective for KidneyIntelX(TM)

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that CPT reimbursement code 0105U for its KidneyIntelX(TM) test has become effective nationally in the United States as of October 1, 2019. The CPT PLA code for KidneyIntelX(TM) was issued on July 1, 2019 and became effective one quarter later to allow insurance payors time to load new test codes into their systems.

Effective immediately, CPT PLA code 0105U can be used to report KidneyIntelX(TM) services to private and public payors throughout the United States for reimbursement. Further details are contained in the Company's announcement dated July 1, 2019. The Company intends to pursue coverage determinations from both Medicare and private insurance payors beginning in 2019 for patients with kidney disease and Type 2 diabetes.

KidneyIntelX(TM) is designed to predict progression of kidney disease and ultimately improve outcomes and health care system economics in patients with Type 2 diabetes and existing kidney disease. KidneyIntelX(TM) uses machine-learning algorithms to assess a combination of predictive blood-based biomarkers and features from a patient's electronic health record to generate a prognostic risk score for rapid-progression of kidney disease.

One of the greatest drivers of health care cost today is patients with rapidly-progressing diabetic kidney disease who are not identified in time and who face progressive kidney failure and unplanned transition to dialysis. Approximately 12 million people have diabetic kidney disease in the United States(1) . Each year kidney disease results in the death of more people than breast and prostate cancer(2) .

The CPT terminology is the most widely accepted medical nomenclature used across the US to report medical, surgical, radiology, laboratory, anaesthesiology, genomic sequencing, evaluation and management services under public and private health insurance programmes. The CPT PLA code awarded to KidneyIntelX(TM) is a recent addition to the CPT Code set known as a CPT Proprietary Laboratory Analysis (PLA) Code. PLA codes are alpha-numeric CPT codes with a corresponding descriptor for labs or manufacturers that want to identify their test more specifically.

CPT PLA codes describe proprietary clinical laboratory analyses and can be provided either by a single ("solesource") laboratory or licensed or marketed to multiple providing laboratories for tests that are cleared or approved by the US Food and Drug Administration. These codes include advanced diagnostic laboratory tests (ADLTs) and clinical diagnostic laboratory tests (CDLTs) as defined under the Protecting Access to Medicare Act (PAMA) of 2014.

Notes

(1) https://cjasn.asnjournals.org/content/12/12/2032

(2) https://www.ncbi.nlm.nih.gov/pubmed/30738630

For further information, please contact:

 
Renalytix AI plc                                                                    www.renalytixai.com 
James McCullough, CEO                                                                   Via Walbrook PR 
 
Stifel (Nominated Adviser & Joint Broker)                                            Tel: [phone] 
Alex Price / Jonathan Senior / Ben Maddison 
 
N+1 Singer (Joint Broker)                                                            Tel: [phone] 
Aubrey Powell / George Tzimas (Corporate Finance) 
Tom Salvesen / Mia Gardner (Corporate Broking) 
 
 
Walbrook PR Limited                                      Tel: [phone] or [e-mail] 
Paul McManus / Lianne Cawthorne                                          Mob: [phone] 
                                                                                                    303 
 
 

About Kidney Disease

Kidney disease is now recognised as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control estimates there that 15% of United States adults or 37 million people currently have chronic kidney disease. It is reported that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day 13 patients die in the United States while waiting for a kidney transplant.

* https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCCKKDQDBKBCCN

(END) Dow Jones Newswires

October 01, 2019 02:00 ET (06:00 GMT)